AstraZeneca

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

EMA's CHMP recommends Fasenra (benralizumab) for EGPA, offering a new treatment option for EU patients with relapses or non-response to standard treatment. Fasenra, already available for severe eosinophilic asthma, targets IL-5 receptor alpha to deplete eosinophils, potentially reducing glucocorticoid use. MANDARA trial data supports its efficacy and safety.

Illumina welcomed the ECJ's judgment on GRAIL acquisition; Moffitt Cancer Center and AstraZeneca collaborate on cell therapies; Ginkgo Bioworks introduced Ginkgo Automation; UTHealth Houston and OpenAI integrate AI in healthcare; 10x Genomics' platforms used in glioblastoma research; Generate:Biomedicines and Novartis collaborate on protein therapeutics; Firefly Neuroscience advances AI in neuroscience drug development; Scale Bio partners with CZI in the 100 Million Cell Challenge; Oracle launches CancerMPact Treatment Architecture Trends; Verseon's VersAI outperforms Google's AI; MilliporeSigma introduces Mobius ADC Reactor; Gilead and Genesis Therapeutics collaborate on small molecule therapies; Primrose Bio and ExPLoRNA partner on mRNA medicines; UC College of Medicine and Cincinnati Children’s Hospital find new drug discovery methods.

Moffitt Cancer Center collaborates with AstraZeneca to accelerate cell therapy development; SWOG develops a risk prediction model for advanced cancer patients in clinical trials; UC San Francisco launches a TBI drug development trial; Ohio State University tests a new DHODH inhibitor for cancer; UTHealth Houston integrates OpenAI's ChatGPT into healthcare education; Rice University and MD Anderson launch the Center for Operations Research in Cancer; Komodo Health introduces MapAI and MapExplorer; Splash Clinical partners with Cambridge Cognition for CNS trial recruitment; Veeva Systems releases Veeva Site Connect; Clinical ink launches EDCXtra, an integrated EDC system.

FluMist Home, a nasal spray flu vaccine, is now approved for self-administration at home for adults under 50 and children aged 2 and up, offering convenience and accessibility. Available from 2025, it uses weakened flu viruses to stimulate immunity and is delivered via home delivery. The FDA hopes this option will boost vaccination rates, as flu vaccination is crucial for public health.

FDA approves first at-home nasal spray flu vaccine, FluMist, available online with prescription starting next year. AstraZeneca will supply to a third-party online pharmacy for screening and administration.

The phase 3 trial TROPION-Breast01 found that datopotamab deruxtecan (Dato-DXd) did not achieve statistical significance in overall survival (OS) for patients with inoperable or metastatic HR+, HER2- breast cancer. Dato-DXd previously met the primary endpoint of progression-free survival (PFS) compared to chemotherapy. The trial assessed Dato-DXd's efficacy and safety against chemotherapy in patients who had progressed on endocrine therapy and at least one systemic therapy.

The U.S. general anesthesia drugs market is projected to grow from USD 1.98 Billion in 2024 to USD 2.56 Billion by 2033, driven by increasing surgical procedures, technological advancements, and regulatory updates. Key segments include propofol, intravenous drugs, knee and hip replacements, and hospitals, with ambulatory surgical centers expected to grow fastest. Major players include GE Healthcare, Pfizer, and Hospira Inc.

The FDA approves the first nasal flu vaccine, FluMist, for self-administration at home, offering greater convenience and accessibility. FluMist, available for those aged 2 to 49 with a prescription, can be administered by the recipient or a caregiver aged 18 or older. This approval aims to enhance public health by increasing vaccination options against influenza, which annually causes millions of illnesses, hospitalizations, and deaths in the U.S.

ALXN2220, a novel monoclonal antibody for ATTR amyloidosis with cardiomyopathy, received fast track designation from the FDA, aiming to address unmet needs in serious medical conditions.